Current Edition

AbbVie

AbbVie’s Rinvoq notches Crohn’s disease win amid classwide JAK safety concerns

AbbVie’s blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn’s disease patients, potentially adding another arrow to the company’s post-Humira quiver. The …

Continue Reading →
Crohn's disease

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop …

Continue Reading →